Other languages Amgen Inc. Buenos Aires S.E.

Equities

End-of-day quote Buenos Aires S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
13,942 ^ARS	+4.20%		+10.93%	+49.37%

06-25	Out with AI, in with defensive stocks
06-21	US FDA approves Roche's drug for a chronic blood disorder	RE

Badaboum	06-25
Valores destacados al cierre del mercado norteamericano	06-25
Borsa di Italia: Bang!	06-25
Bolsa de Madrid: ¡Bang!	06-25
US FDA approves Roche's drug for a chronic blood disorder	06-21
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	06-14
Sector Update: Health Care Stocks Softer Friday Afternoon	06-14
Wall Street finit contrastée, nouveaux records pour Nasdaq et S&P 500	06-13
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	06-12
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints	06-05
Amgen's drug meets main goal in late-stage study for rare disease	06-05
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)	06-05
Amgen Inc. Appoints Dr. Mary E. Klotman as Director	06-03
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment	05-28
Previsiones de venta de medicamentos para adelgazar suben a 150.000 millones de dólares	05-28
Weight-loss drug forecasts jump to $150 billion as supply grows	05-28
Sandoz : AMM pour Wyost et Jubbonti dans l'UE	05-22
Un test de Roche reçoit la désignation de dispositif révolutionnaire aux USA	05-22
Sandoz: feu vert de la Commission européenne pour Wyost et Jubbonti	05-22

No results for this search